Lenvatinib With Taxane Drugs Treatment for Advanced Gastric Cancer
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to study the safety and efficacy of lenvatinib combined
with single-agent taxanes therapy in patients with HER2-negative advanced gastric cancer that
have failed at the standard first-line therapy.